{"id":1183,"date":"2024-08-01T09:30:31","date_gmt":"2024-08-01T01:30:31","guid":{"rendered":"https:\/\/flcube.com\/?p=1183"},"modified":"2024-10-28T12:15:58","modified_gmt":"2024-10-28T04:15:58","slug":"biocytogen-strikes-licensing-deal-with-ideaya-for-potential-first-in-class-bsadc-program","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=1183","title":{"rendered":"Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program"},"content":{"rendered":"\n

China-based Biocytogen (HKG: 2315<\/a>) has entered into an option and licensing agreement with US-based IDEAYA Biosciences Inc. (NASDAQ: IDYA<\/a>) for the development of Biocytogen’s B7H3\/PTK7 program, a potential first-in-class bispecific antibody drug conjugate (BsADC). The agreement grants IDEAYA the option for an exclusive worldwide license to the drug, which has shown promise in targeting multiple solid tumor types, including significant prevalence in lung, colorectal, and head and neck cancers.<\/p>\n\n\n\n

Under the terms of the deal, Biocytogen will receive an upfront payment and is eligible for an option exercise fee, development and regulatory milestones, and commercial milestone payments upon the exercise of the option by IDEAYA. Additionally, Biocytogen is set to receive single-digit royalties on net sales. The total potential value of the upfront, option exercise, and milestone payments aggregates to USD 406.5 million, including development and regulatory milestones worth USD 100.0 million.<\/p>\n\n\n\n

Pre-clinical data for the B7H3\/PTK7 topoisomerase-I-inhibitor-payload BsADC program indicate its potential as a monotherapy agent and in combination with other DDR-based therapies in IDEAYA’s pipeline, such as the PARG inhibitor IDE161. Biocytogen anticipates the nomination of a development candidate for the B7H3\/PTK7 program in the second half of 2024.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Biocytogen (HKG: 2315) has entered into an option and licensing agreement with US-based IDEAYA…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,1519,1214,443,1215],"class_list":["post-1183","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-biocytogen-pharmaceuticals","tag-hkg-2315","tag-ideaya-biosciences","tag-nasdaq-idya"],"yoast_head":"\nBiocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Biocytogen (HKG: 2315) has entered into an option and licensing agreement with US-based IDEAYA Biosciences Inc. (NASDAQ: IDYA) for the development of Biocytogen's B7H3\/PTK7 program, a potential first-in-class bispecific antibody drug conjugate (BsADC). The agreement grants IDEAYA the option for an exclusive worldwide license to the drug, which has shown promise in targeting multiple solid tumor types, including significant prevalence in lung, colorectal, and head and neck cancers.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=1183\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=1183\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-01T01:30:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-28T04:15:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1183#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1183\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program\",\"datePublished\":\"2024-08-01T01:30:31+00:00\",\"dateModified\":\"2024-10-28T04:15:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1183\"},\"wordCount\":209,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Biocytogen Pharmaceuticals\",\"HKG: 2315\",\"IDEAYA Biosciences\",\"NASDAQ: IDYA\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1183#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1183\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=1183\",\"name\":\"Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-08-01T01:30:31+00:00\",\"dateModified\":\"2024-10-28T04:15:58+00:00\",\"description\":\"China-based Biocytogen (HKG: 2315) has entered into an option and licensing agreement with US-based IDEAYA Biosciences Inc. (NASDAQ: IDYA) for the development of Biocytogen's B7H3\\\/PTK7 program, a potential first-in-class bispecific antibody drug conjugate (BsADC). The agreement grants IDEAYA the option for an exclusive worldwide license to the drug, which has shown promise in targeting multiple solid tumor types, including significant prevalence in lung, colorectal, and head and neck cancers.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1183#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1183\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1183#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program - Insight, China's Pharmaceutical Industry","description":"China-based Biocytogen (HKG: 2315) has entered into an option and licensing agreement with US-based IDEAYA Biosciences Inc. (NASDAQ: IDYA) for the development of Biocytogen's B7H3\/PTK7 program, a potential first-in-class bispecific antibody drug conjugate (BsADC). The agreement grants IDEAYA the option for an exclusive worldwide license to the drug, which has shown promise in targeting multiple solid tumor types, including significant prevalence in lung, colorectal, and head and neck cancers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=1183","og_locale":"en_US","og_type":"article","og_title":"Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=1183","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-08-01T01:30:31+00:00","article_modified_time":"2024-10-28T04:15:58+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=1183#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=1183"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program","datePublished":"2024-08-01T01:30:31+00:00","dateModified":"2024-10-28T04:15:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=1183"},"wordCount":209,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Biocytogen Pharmaceuticals","HKG: 2315","IDEAYA Biosciences","NASDAQ: IDYA"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=1183#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=1183","url":"https:\/\/flcube.com\/?p=1183","name":"Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-08-01T01:30:31+00:00","dateModified":"2024-10-28T04:15:58+00:00","description":"China-based Biocytogen (HKG: 2315) has entered into an option and licensing agreement with US-based IDEAYA Biosciences Inc. (NASDAQ: IDYA) for the development of Biocytogen's B7H3\/PTK7 program, a potential first-in-class bispecific antibody drug conjugate (BsADC). The agreement grants IDEAYA the option for an exclusive worldwide license to the drug, which has shown promise in targeting multiple solid tumor types, including significant prevalence in lung, colorectal, and head and neck cancers.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=1183#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=1183"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=1183#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1183","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1183"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1183\/revisions"}],"predecessor-version":[{"id":6403,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1183\/revisions\/6403"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1183"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1183"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1183"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}